[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgx55aQBZJhFHSesMgG5_XcYt2Y-XsXrvQhLtlJDMJfU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":9,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Mallinckrodt",[4,6],"Mallinckrodt ARD LLC",90,false,0,30,10032,3,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Healthy",8,{"name":18,"count":19},"Pain",7,{"name":21,"count":22},"Fever",5,{"name":24,"count":25},"Acute Pain",4,{"name":27,"count":12},"Lung Disease",{"name":29,"count":12},"Hepatorenal Syndrome",{"name":31,"count":32},"Surgical Bleeding",2,{"name":34,"count":32},"Pharmacokinetics",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,164,242,289,336,362,386,404,422,440,458,483,547,616,667,726,770,812,848,870,892,927,960,982,1011,1029,1055,1073,1091,1114,1139,1157,1175,1193,1211,1235,1253,1294,1316,1339,1365,1383,1406,1430,1453,1478,1496,1521,1546,1564,1589,1607,1638,1660,1688,1710,1740,1762,1786,1804,1827,1849,1867,1892,1916,1941,1959,1977,2000,2018,2042,2060,2085],{"intervention":45,"totalTrials":46,"cells":47},"IV Acetaminophen",10,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":62,"PHASE3":64,"PHASE4":125,"NA":162},{"trials":49,"activeCount":9},[],{"trials":51,"activeCount":9},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":61},"NCT00493246","Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients","COMPLETED",[38],"2008-11","2007-06",75,[18,21],[45,45],{"trials":63,"activeCount":9},[],{"trials":65,"activeCount":9},[66,76,86,97,104,113],{"nctId":67,"briefTitle":68,"status":55,"phases":69,"primaryCompletion":70,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":75},"NCT00598702","Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients",[40],"2008-12","2009-01","2008-01",100,[18,21],[45],{"nctId":77,"briefTitle":78,"status":55,"phases":79,"primaryCompletion":80,"completion":80,"start":81,"enrollment":82,"conditions":83,"interventions":84},"NCT00564486","Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain",[40],"2008-09","2007-11",244,[18],[85,85,45,45],"IV Placebo",{"nctId":87,"briefTitle":88,"status":55,"phases":89,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":95},"NCT01635101","A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients",[40],"2015-08","2015-11","2012-06",197,[24],[45,96],"IV Control",{"nctId":98,"briefTitle":99,"status":55,"phases":100,"primaryCompletion":57,"completion":57,"start":72,"enrollment":101,"conditions":102,"interventions":103},"NCT00598559","Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients",[40],213,[24,21],[45],{"nctId":105,"briefTitle":106,"status":55,"phases":107,"primaryCompletion":108,"completion":108,"start":58,"enrollment":109,"conditions":110,"interventions":111},"NCT00493311","Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males",[40],"2007-10",60,[21],[85,45,112],"Reference Standard Endotoxin",{"nctId":114,"briefTitle":115,"status":55,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":123},"NCT00399568","Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery",[40],"2007-09","2006-11",331,[121,122],"Postoperative Pain","Hysterectomy",[45,124],"IV Placebo 100 mL solution",{"trials":126,"activeCount":9},[127,141,153],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT02746263","Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain","TERMINATED",[41],"2016-05-05","2016-04-27",1,[136],"Acute Pain, Postoperative",[138,139,140],"IV acetaminophen","Oral acetaminophen","Morphine",{"nctId":142,"briefTitle":143,"status":55,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT02848729","Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen",[41],"2016-03","2016-02",50,[18],[150,45,151,152],"Oral Acetaminophen","IV Morphine","Saline",{"nctId":154,"briefTitle":155,"status":55,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT02678416","Reduction in Pain Intensity Following IV or Oral Pain-relieving Products",[41],"2016-06-13","2015-12-07",79,[18],[45,150],{"trials":163,"activeCount":9},[],{"intervention":165,"totalTrials":166,"cells":167},"Acthar Gel",6,{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":176,"NA":240},{"trials":169,"activeCount":9},[],{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"trials":175,"activeCount":9},[],{"trials":177,"activeCount":9},[178,189,199,210,220,230],{"nctId":179,"briefTitle":180,"status":55,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT02919761","Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis",[41],"2018-10-17","2019-02-13","2016-11-07",259,[187],"Arthritis, Rheumatoid",[165],{"nctId":190,"briefTitle":191,"status":55,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT03320070","Acthar Gel in Participants With Pulmonary Sarcoidosis",[41],"2021-11-15","2018-02-21",55,[197],"Sarcoidosis, Pulmonary",[165],{"nctId":200,"briefTitle":201,"status":55,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT02953821","Acthar Gel for Active Systemic Lupus Erythematosus (SLE)",[41],"2019-07-31","2019-10-25","2016-12-16",172,[208],"Lupus Erythematosus, Systemic",[165],{"nctId":211,"briefTitle":212,"status":55,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT02633046","Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria",[41],"2020-08-27","2016-10-10",63,[218],"Idiopathic Focal Segmental Glomerulosclerosis",[165],{"nctId":221,"briefTitle":222,"status":130,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT03126760","Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)",[41],"2020-07-14","2017-05-22",35,[228],"Multiple Sclerosis, Relapsing-Remitting",[165],{"nctId":231,"briefTitle":232,"status":130,"phases":233,"primaryCompletion":224,"completion":224,"start":234,"enrollment":22,"conditions":235,"interventions":239},"NCT03656692","Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)",[41],"2018-10-05",[236,237,238],"Uveitis, Posterior","Uveitis, Intermediate","Panuveitis",[165],{"trials":241,"activeCount":9},[],{"intervention":243,"totalTrials":12,"cells":244},"Acthar",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":263,"NA":287},{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"trials":250,"activeCount":9},[],{"trials":252,"activeCount":9},[253],{"nctId":254,"briefTitle":255,"status":130,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":262},"NCT03068754","Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)",[39,40],"2019-11-25","2017-06-22",143,[261],"Amyotrophic Lateral Sclerosis",[243],{"trials":264,"activeCount":9},[265,276],{"nctId":266,"briefTitle":267,"status":55,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT04169061","Impact of Acthar on Everyday Life of Participants With Severe Keratitis",[41],"2020-11-09","2020-12-07","2019-11-13",36,[274],"Keratitis",[243],{"nctId":277,"briefTitle":278,"status":55,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT01753401","Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease",[41],"2015-10","2013-01",38,[284],"Systemic Lupus Erythematosus (SLE)",[243,286],"Steroid Drug",{"trials":288,"activeCount":9},[],{"intervention":290,"totalTrials":12,"cells":291},"Repository Corticotropin",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":293,"activeCount":9},[],{"trials":295,"activeCount":9},[],{"trials":297,"activeCount":9},[298,308],{"nctId":299,"briefTitle":300,"status":55,"phases":301,"primaryCompletion":302,"completion":145,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT01601236","Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients",[39],"2016-01","2012-05",34,[306],"Diabetic Nephropathy",[290],{"nctId":309,"briefTitle":310,"status":55,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":317},"NCT01906658","A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis",[39],"2014-11","2014-12","2013-07",43,[261],[318],"Repository corticotropin",{"trials":320,"activeCount":9},[],{"trials":322,"activeCount":9},[323],{"nctId":324,"briefTitle":325,"status":55,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":109,"conditions":330,"interventions":333},"NCT01386554","Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients",[41],"2016-11-21","2017-05-05","2011-08",[331,332],"Proteinuria","Idiopathic Membranous Nephropathy",[290],{"trials":335,"activeCount":9},[],{"intervention":150,"totalTrials":12,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":360},{"trials":339,"activeCount":9},[],{"trials":341,"activeCount":9},[],{"trials":343,"activeCount":9},[],{"trials":345,"activeCount":9},[],{"trials":347,"activeCount":9},[348,352,356],{"nctId":128,"briefTitle":129,"status":130,"phases":349,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":350,"interventions":351},[41],[136],[138,139,140],{"nctId":142,"briefTitle":143,"status":55,"phases":353,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":354,"interventions":355},[41],[18],[150,45,151,152],{"nctId":154,"briefTitle":155,"status":55,"phases":357,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":358,"interventions":359},[41],[18],[45,150],{"trials":361,"activeCount":9},[],{"intervention":363,"totalTrials":134,"cells":364},"XARTEMIS XR",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":384},{"trials":366,"activeCount":9},[],{"trials":368,"activeCount":9},[],{"trials":370,"activeCount":9},[],{"trials":372,"activeCount":9},[],{"trials":374,"activeCount":9},[375],{"nctId":376,"briefTitle":377,"status":130,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":383},"NCT02508935","Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain",[41],"2017-04-26","2015-11-20",23,[24],[363],{"trials":385,"activeCount":9},[],{"intervention":140,"totalTrials":134,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":9},[],{"trials":391,"activeCount":9},[],{"trials":393,"activeCount":9},[],{"trials":395,"activeCount":9},[],{"trials":397,"activeCount":9},[398],{"nctId":128,"briefTitle":129,"status":130,"phases":399,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":400,"interventions":401},[41],[136],[138,139,140],{"trials":403,"activeCount":9},[],{"intervention":151,"totalTrials":134,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":9},[],{"trials":409,"activeCount":9},[],{"trials":411,"activeCount":9},[],{"trials":413,"activeCount":9},[],{"trials":415,"activeCount":9},[416],{"nctId":142,"briefTitle":143,"status":55,"phases":417,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":418,"interventions":419},[41],[18],[150,45,151,152],{"trials":421,"activeCount":9},[],{"intervention":152,"totalTrials":134,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":438},{"trials":425,"activeCount":9},[],{"trials":427,"activeCount":9},[],{"trials":429,"activeCount":9},[],{"trials":431,"activeCount":9},[],{"trials":433,"activeCount":9},[434],{"nctId":142,"briefTitle":143,"status":55,"phases":435,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":436,"interventions":437},[41],[18],[150,45,151,152],{"trials":439,"activeCount":9},[],{"intervention":286,"totalTrials":134,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":456},{"trials":443,"activeCount":9},[],{"trials":445,"activeCount":9},[],{"trials":447,"activeCount":9},[],{"trials":449,"activeCount":9},[],{"trials":451,"activeCount":9},[452],{"nctId":277,"briefTitle":278,"status":55,"phases":453,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":454,"interventions":455},[41],[284],[243,286],{"trials":457,"activeCount":9},[],{"intervention":459,"totalTrials":134,"cells":460},"Indium In-111 pentetreotide",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":481},{"trials":462,"activeCount":9},[],{"trials":464,"activeCount":9},[],{"trials":466,"activeCount":9},[],{"trials":468,"activeCount":9},[],{"trials":470,"activeCount":9},[471],{"nctId":472,"briefTitle":473,"status":130,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT00944372","Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors",[41],"2005-08","2003-07",150,[479],"Solid Tumors",[459],{"trials":482,"activeCount":9},[],{"intervention":484,"totalTrials":22,"cells":485},"Nitric Oxide",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":531,"PHASE4":543,"NA":545},{"trials":487,"activeCount":9},[],{"trials":489,"activeCount":9},[],{"trials":491,"activeCount":9},[492,500,512,522],{"nctId":493,"briefTitle":494,"status":55,"phases":495,"primaryCompletion":70,"completion":70,"start":496,"enrollment":477,"conditions":497,"interventions":499},"NCT00094887","Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises",[39],"2004-10",[498],"Anemia, Sickle Cell",[484],{"nctId":501,"briefTitle":502,"status":130,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":511},"NCT00568061","Nitric Oxide in Myocardial Infarction Size",[39],"2008-06","2006-06",29,[508,509,510],"Acute Myocardial Infarction","ST Elevation MI","STEMI",[484],{"nctId":513,"briefTitle":514,"status":55,"phases":515,"primaryCompletion":504,"completion":504,"start":516,"enrollment":517,"conditions":518,"interventions":520},"NCT00570245","Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation",[39],"2005-04",49,[519],"Lung Transplantation",[521,521],"Nitric oxide",{"nctId":523,"briefTitle":524,"status":55,"phases":525,"primaryCompletion":504,"completion":526,"start":476,"enrollment":477,"conditions":527,"interventions":529},"NCT00060840","The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation",[39],"2008-07",[528],"Congestive Heart Failure",[484,530],"Nitrogen",{"trials":532,"activeCount":9},[533],{"nctId":534,"briefTitle":535,"status":55,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":542},"NCT00551642","Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies",[40],"2008-03-16","2015-07-17","2005-05-29",800,[27],[521],{"trials":544,"activeCount":9},[],{"trials":546,"activeCount":9},[],{"intervention":548,"totalTrials":22,"cells":549},"Inhaled Nitric Oxide",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":579,"PHASE4":612,"NA":614},{"trials":551,"activeCount":9},[],{"trials":553,"activeCount":9},[],{"trials":555,"activeCount":9},[556,568],{"nctId":557,"briefTitle":558,"status":130,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":19,"conditions":562,"interventions":567},"NCT00041574","Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide",[39],"2005-12","2002-04",[563,27,564,565,566],"Pulmonary Hypertension","Sickle Cell Disease","Cardiac Transplant","Lung Transplant",[548],{"nctId":569,"briefTitle":570,"status":130,"phases":571,"primaryCompletion":572,"completion":572,"start":573,"enrollment":12,"conditions":574,"interventions":576},"NCT00782652","The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients",[39],"2007-02","2006-03",[575],"Right Ventricular Infarction",[577,578],"inhaled nitric oxide","nitrogen gas",{"trials":580,"activeCount":9},[581,592,602],{"nctId":582,"briefTitle":583,"status":130,"phases":584,"primaryCompletion":585,"completion":585,"start":586,"enrollment":195,"conditions":587,"interventions":590},"NCT00041561","Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics",[40],"2004-12","2002-01",[588,589],"Respiratory Insufficiency","Anoxemia",[591,577],"Nitrogen gas",{"nctId":593,"briefTitle":594,"status":595,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":9,"conditions":599,"interventions":601},"NCT00922532","Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure","WITHDRAWN",[40],"2011-10","2009-11",[600],"Hypoxic Respiratory Failure With Pulmonary Hypertension",[548],{"nctId":603,"briefTitle":604,"status":55,"phases":605,"primaryCompletion":606,"completion":607,"start":598,"enrollment":608,"conditions":609,"interventions":611},"NCT00931632","Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants",[40],"2013-05","2014-05",451,[610],"Bronchopulmonary Dysplasia",[548],{"trials":613,"activeCount":9},[],{"trials":615,"activeCount":9},[],{"intervention":617,"totalTrials":25,"cells":618},"COV155",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":637,"PHASE3":639,"PHASE4":663,"NA":665},{"trials":620,"activeCount":9},[],{"trials":622,"activeCount":9},[623,630],{"nctId":624,"briefTitle":625,"status":55,"phases":626,"primaryCompletion":627,"completion":627,"start":627,"enrollment":10,"conditions":628,"interventions":629},"NCT02561741","Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions",[38],"2012-12",[34],[617],{"nctId":631,"briefTitle":625,"status":55,"phases":632,"primaryCompletion":633,"completion":633,"start":633,"enrollment":634,"conditions":635,"interventions":636},"NCT02561650",[38],"2011-12",48,[34],[617],{"trials":638,"activeCount":9},[],{"trials":640,"activeCount":9},[641,651],{"nctId":642,"briefTitle":643,"status":55,"phases":644,"primaryCompletion":606,"completion":314,"start":645,"enrollment":646,"conditions":647,"interventions":650},"NCT01743625","Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain",[40],"2012-11",406,[648,649],"Pain, Postoperative","Bunion",[617],{"nctId":652,"briefTitle":653,"status":55,"phases":654,"primaryCompletion":655,"completion":656,"start":645,"enrollment":657,"conditions":658,"interventions":662},"NCT01722864","Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)",[40],"2013-02","2013-08",153,[659,660,661],"Osteoarthritis, Knee","Osteoarthritis, Hip","Chronic Low Back Pain",[617],{"trials":664,"activeCount":9},[],{"trials":666,"activeCount":9},[],{"intervention":668,"totalTrials":25,"cells":669},"nitric oxide for inhalation",{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":697,"PHASE4":722,"NA":724},{"trials":671,"activeCount":9},[],{"trials":673,"activeCount":9},[],{"trials":675,"activeCount":9},[676,687],{"nctId":677,"briefTitle":678,"status":130,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":19,"conditions":682,"interventions":685},"NCT00041548","Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation",[38,39],"2005-06","2002-05",[27,683,684],"Hypoxemia","Respiratory Acidosis",[668,686],"Oxygen",{"nctId":688,"briefTitle":689,"status":55,"phases":690,"primaryCompletion":70,"completion":70,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT00570349","Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis",[38,39],"2004-07",18,[694],"Cystic Fibrosis",[696,696,530],"Nitric Oxide for Inhalation",{"trials":698,"activeCount":9},[699,712],{"nctId":700,"briefTitle":701,"status":55,"phases":702,"primaryCompletion":703,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":709},"NCT00626028","Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing",[40],"2010-02","2004-09",136,[707,708],"Idiopathic Pulmonary Arterial Hypertension","Cardiomyopathy",[710,686,711],"Nitric Oxide for inhalation","Nitric Oxide plus Oxygen",{"nctId":713,"briefTitle":714,"status":130,"phases":715,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT00060450","Inhaled Nitric Oxide in Prevention\u002FTreatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation",[40],"2006-09","2001-08",84,[720],"Ischemia-Reperfusion Injury",[668],{"trials":723,"activeCount":9},[],{"trials":725,"activeCount":9},[],{"intervention":727,"totalTrials":12,"cells":728},"Fibrocaps",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":745,"PHASE4":766,"NA":768},{"trials":730,"activeCount":9},[],{"trials":732,"activeCount":9},[],{"trials":734,"activeCount":9},[735],{"nctId":736,"briefTitle":737,"status":55,"phases":738,"primaryCompletion":739,"completion":597,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT01256190","A Study of Fibrocaps in Liver Surgery in the Netherlands",[39],"2011-09","2010-12",56,[743],"Postoperative Hemorrhage",[727],{"trials":746,"activeCount":9},[747,754],{"nctId":748,"briefTitle":749,"status":55,"phases":750,"primaryCompletion":90,"completion":90,"start":312,"enrollment":477,"conditions":751,"interventions":752},"NCT02284256","A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery",[40],[31],[727,753],"TachoSil",{"nctId":755,"briefTitle":756,"status":55,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT01527357","A Study of Fibrocaps™ in Surgical Bleeding",[40],"2013-04-24","2013-06-01","2012-05-21",721,[763],"Mild or Moderate Surgical Bleeding",[727,765],"Gelatin sponge",{"trials":767,"activeCount":9},[],{"trials":769,"activeCount":9},[],{"intervention":771,"totalTrials":12,"cells":772},"Terlipressin",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":808,"NA":810},{"trials":774,"activeCount":9},[],{"trials":776,"activeCount":9},[],{"trials":778,"activeCount":9},[],{"trials":780,"activeCount":9},[781,790,799],{"nctId":782,"briefTitle":783,"status":55,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT02770716","Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1",[40],"2019-07-24","2016-07-13",300,[29],[771],{"nctId":791,"briefTitle":792,"status":55,"phases":793,"primaryCompletion":573,"completion":716,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT00089570","Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1",[40],"2004-06",112,[29],[798],"terlipressin",{"nctId":800,"briefTitle":801,"status":55,"phases":802,"primaryCompletion":655,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":807},"NCT01143246","A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin",[40],"2013-05-10","2010-10-11",196,[29],[771],{"trials":809,"activeCount":9},[],{"trials":811,"activeCount":9},[],{"intervention":813,"totalTrials":32,"cells":814},"COV795",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":844,"NA":846},{"trials":816,"activeCount":9},[],{"trials":818,"activeCount":9},[],{"trials":820,"activeCount":9},[],{"trials":822,"activeCount":9},[823,834],{"nctId":824,"briefTitle":825,"status":55,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":833},"NCT01451385","Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain",[40],"2012-06-18","2011-09-20",376,[831,832],"Osteoarthritis","Low Back Pain",[813],{"nctId":835,"briefTitle":836,"status":55,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT01484652","Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension",[40],"2012-08","2012-09","2011-11",329,[648,649],[813],{"trials":845,"activeCount":9},[],{"trials":847,"activeCount":9},[],{"intervention":591,"totalTrials":32,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":860,"PHASE4":866,"NA":868},{"trials":851,"activeCount":9},[],{"trials":853,"activeCount":9},[],{"trials":855,"activeCount":9},[856],{"nctId":569,"briefTitle":570,"status":130,"phases":857,"primaryCompletion":572,"completion":572,"start":573,"enrollment":12,"conditions":858,"interventions":859},[39],[575],[577,578],{"trials":861,"activeCount":9},[862],{"nctId":582,"briefTitle":583,"status":130,"phases":863,"primaryCompletion":585,"completion":585,"start":586,"enrollment":195,"conditions":864,"interventions":865},[40],[588,589],[591,577],{"trials":867,"activeCount":9},[],{"trials":869,"activeCount":9},[],{"intervention":85,"totalTrials":32,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":888,"NA":890},{"trials":873,"activeCount":9},[],{"trials":875,"activeCount":9},[],{"trials":877,"activeCount":9},[],{"trials":879,"activeCount":9},[880,884],{"nctId":77,"briefTitle":78,"status":55,"phases":881,"primaryCompletion":80,"completion":80,"start":81,"enrollment":82,"conditions":882,"interventions":883},[40],[18],[85,85,45,45],{"nctId":105,"briefTitle":106,"status":55,"phases":885,"primaryCompletion":108,"completion":108,"start":58,"enrollment":109,"conditions":886,"interventions":887},[40],[21],[85,45,112],{"trials":889,"activeCount":9},[],{"trials":891,"activeCount":9},[],{"intervention":893,"totalTrials":32,"cells":894},"Standard of Care",{"EARLY_PHASE1":895,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":923,"NA":925},{"trials":896,"activeCount":9},[897],{"nctId":898,"briefTitle":899,"status":55,"phases":900,"primaryCompletion":901,"completion":901,"start":840,"enrollment":109,"conditions":902,"interventions":904},"NCT01380535","Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)",[37],"2015-03",[903],"Chronic Graft Versus Host Disease",[905,893],"ECP Methoxsalen",{"trials":907,"activeCount":9},[],{"trials":909,"activeCount":9},[],{"trials":911,"activeCount":9},[912],{"nctId":913,"briefTitle":914,"status":595,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":9,"conditions":919,"interventions":921},"NCT04128462","MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function",[40],"2025-04","2025-07","2021-11",[920],"Hepatic Encephalopathy",[922,893],"MNK-6105",{"trials":924,"activeCount":9},[],{"trials":926,"activeCount":9},[],{"intervention":928,"totalTrials":32,"cells":929},"OROS hydromorphone",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":956,"NA":958},{"trials":931,"activeCount":9},[],{"trials":933,"activeCount":9},[],{"trials":935,"activeCount":9},[],{"trials":937,"activeCount":9},[938,949],{"nctId":939,"briefTitle":940,"status":55,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT00631319","A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain",[40],"2009-04","2009-06","2008-02",343,[947],"Chronic Pain",[928],{"nctId":950,"briefTitle":951,"status":55,"phases":952,"primaryCompletion":71,"completion":71,"start":108,"enrollment":953,"conditions":954,"interventions":955},"NCT00549042","Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain",[40],459,[661],[928],{"trials":957,"activeCount":9},[],{"trials":959,"activeCount":9},[],{"intervention":686,"totalTrials":32,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":972,"PHASE4":978,"NA":980},{"trials":963,"activeCount":9},[],{"trials":965,"activeCount":9},[],{"trials":967,"activeCount":9},[968],{"nctId":677,"briefTitle":678,"status":130,"phases":969,"primaryCompletion":680,"completion":680,"start":681,"enrollment":19,"conditions":970,"interventions":971},[38,39],[27,683,684],[668,686],{"trials":973,"activeCount":9},[974],{"nctId":700,"briefTitle":701,"status":55,"phases":975,"primaryCompletion":703,"completion":703,"start":704,"enrollment":705,"conditions":976,"interventions":977},[40],[707,708],[710,686,711],{"trials":979,"activeCount":9},[],{"trials":981,"activeCount":9},[],{"intervention":983,"totalTrials":32,"cells":984},"Reference standard endotoxin",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":1007,"NA":1009},{"trials":986,"activeCount":9},[],{"trials":988,"activeCount":9},[],{"trials":990,"activeCount":9},[],{"trials":992,"activeCount":9},[993,1003],{"nctId":994,"briefTitle":995,"status":55,"phases":996,"primaryCompletion":108,"completion":108,"start":997,"enrollment":998,"conditions":999,"interventions":1000},"NCT00564629","Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males",[40],"2007-08",105,[21],[1001,1002,983],"Intravenous acetaminophen plus oral placebo","Oral acetaminophen plus IV placebo",{"nctId":105,"briefTitle":106,"status":55,"phases":1004,"primaryCompletion":108,"completion":108,"start":58,"enrollment":109,"conditions":1005,"interventions":1006},[40],[21],[85,45,112],{"trials":1008,"activeCount":9},[],{"trials":1010,"activeCount":9},[],{"intervention":753,"totalTrials":134,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1025,"NA":1027},{"trials":1014,"activeCount":9},[],{"trials":1016,"activeCount":9},[],{"trials":1018,"activeCount":9},[],{"trials":1020,"activeCount":9},[1021],{"nctId":748,"briefTitle":749,"status":55,"phases":1022,"primaryCompletion":90,"completion":90,"start":312,"enrollment":477,"conditions":1023,"interventions":1024},[40],[31],[727,753],{"trials":1026,"activeCount":9},[],{"trials":1028,"activeCount":9},[],{"intervention":1030,"totalTrials":134,"cells":1031},"IK-3001",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1051,"NA":1053},{"trials":1033,"activeCount":9},[],{"trials":1035,"activeCount":9},[],{"trials":1037,"activeCount":9},[],{"trials":1039,"activeCount":9},[1040],{"nctId":1041,"briefTitle":1042,"status":55,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":692,"conditions":1047,"interventions":1050},"NCT01959828","Confirmatory Study of IK-3001 in Japanese Subjects With Peri-\u002FPost-op Pulmonary Hypertension Assoc. With Cardiac Surgery",[40],"2014-03","2014-07","2013-09",[1048,1049],"Hypertension, Pulmonary","Ventricular Dysfunction, Left",[1030],{"trials":1052,"activeCount":9},[],{"trials":1054,"activeCount":9},[],{"intervention":96,"totalTrials":134,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":9},[],{"trials":1060,"activeCount":9},[],{"trials":1062,"activeCount":9},[],{"trials":1064,"activeCount":9},[1065],{"nctId":87,"briefTitle":88,"status":55,"phases":1066,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":1067,"interventions":1068},[40],[24],[45,96],{"trials":1070,"activeCount":9},[],{"trials":1072,"activeCount":9},[],{"intervention":922,"totalTrials":134,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":9},[],{"trials":1078,"activeCount":9},[],{"trials":1080,"activeCount":9},[],{"trials":1082,"activeCount":9},[1083],{"nctId":913,"briefTitle":914,"status":595,"phases":1084,"primaryCompletion":916,"completion":917,"start":918,"enrollment":9,"conditions":1085,"interventions":1086},[40],[920],[922,893],{"trials":1088,"activeCount":9},[],{"trials":1090,"activeCount":9},[],{"intervention":1092,"totalTrials":134,"cells":1093},"Hydromorphone HCl ER",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1110,"NA":1112},{"trials":1095,"activeCount":9},[],{"trials":1097,"activeCount":9},[],{"trials":1099,"activeCount":9},[],{"trials":1101,"activeCount":9},[1102],{"nctId":1103,"briefTitle":1104,"status":130,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":22,"conditions":1108,"interventions":1109},"NCT02321319","Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients",[40],"2019-02-04","2017-03-11",[947],[1092],{"trials":1111,"activeCount":9},[],{"trials":1113,"activeCount":9},[],{"intervention":1115,"totalTrials":134,"cells":1116},"Lubiprostone",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1135,"NA":1137},{"trials":1118,"activeCount":9},[],{"trials":1120,"activeCount":9},[],{"trials":1122,"activeCount":9},[],{"trials":1124,"activeCount":9},[1125],{"nctId":1126,"briefTitle":1127,"status":55,"phases":1128,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT01993875","Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation",[40],"2014-01","2013-10",164,[1133],"Chronic Idiopathic Constipation",[1115],{"trials":1136,"activeCount":9},[],{"trials":1138,"activeCount":9},[],{"intervention":1001,"totalTrials":134,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":9},[],{"trials":1144,"activeCount":9},[],{"trials":1146,"activeCount":9},[],{"trials":1148,"activeCount":9},[1149],{"nctId":994,"briefTitle":995,"status":55,"phases":1150,"primaryCompletion":108,"completion":108,"start":997,"enrollment":998,"conditions":1151,"interventions":1152},[40],[21],[1001,1002,983],{"trials":1154,"activeCount":9},[],{"trials":1156,"activeCount":9},[],{"intervention":1002,"totalTrials":134,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":9},[],{"trials":1162,"activeCount":9},[],{"trials":1164,"activeCount":9},[],{"trials":1166,"activeCount":9},[1167],{"nctId":994,"briefTitle":995,"status":55,"phases":1168,"primaryCompletion":108,"completion":108,"start":997,"enrollment":998,"conditions":1169,"interventions":1170},[40],[21],[1001,1002,983],{"trials":1172,"activeCount":9},[],{"trials":1174,"activeCount":9},[],{"intervention":711,"totalTrials":134,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":9},[],{"trials":1180,"activeCount":9},[],{"trials":1182,"activeCount":9},[],{"trials":1184,"activeCount":9},[1185],{"nctId":700,"briefTitle":701,"status":55,"phases":1186,"primaryCompletion":703,"completion":703,"start":704,"enrollment":705,"conditions":1187,"interventions":1188},[40],[707,708],[710,686,711],{"trials":1190,"activeCount":9},[],{"trials":1192,"activeCount":9},[],{"intervention":765,"totalTrials":134,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":9},[],{"trials":1198,"activeCount":9},[],{"trials":1200,"activeCount":9},[],{"trials":1202,"activeCount":9},[1203],{"nctId":755,"briefTitle":756,"status":55,"phases":1204,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":1205,"interventions":1206},[40],[763],[727,765],{"trials":1208,"activeCount":9},[],{"trials":1210,"activeCount":9},[],{"intervention":1212,"totalTrials":134,"cells":1213},"Methoxsalen+ECP, Methylprednisolone",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1231,"NA":1233},{"trials":1215,"activeCount":9},[],{"trials":1217,"activeCount":9},[],{"trials":1219,"activeCount":9},[],{"trials":1221,"activeCount":9},[1222],{"nctId":1223,"briefTitle":1224,"status":130,"phases":1225,"primaryCompletion":58,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT00282503","Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease",[40],"2006-01",19,[1229],"Acute Graft-versus-Host Disease",[1212],{"trials":1232,"activeCount":9},[],{"trials":1234,"activeCount":9},[],{"intervention":124,"totalTrials":134,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":9},[],{"trials":1240,"activeCount":9},[],{"trials":1242,"activeCount":9},[],{"trials":1244,"activeCount":9},[1245],{"nctId":114,"briefTitle":115,"status":55,"phases":1246,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":1247,"interventions":1248},[40],[121,122],[45,124],{"trials":1250,"activeCount":9},[],{"trials":1252,"activeCount":9},[],{"intervention":1254,"totalTrials":12,"cells":1255},"Methoxsalen",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1257,"activeCount":9},[],{"trials":1259,"activeCount":9},[],{"trials":1261,"activeCount":9},[1262,1272,1278],{"nctId":1263,"briefTitle":1264,"status":55,"phases":1265,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1271},"NCT00054613","Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease",[39],"2004-03","2002-06",72,[1270],"Graft-versus-Host Disease",[1254],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1275,"completion":794,"start":1267,"enrollment":109,"conditions":1276,"interventions":1277},"NCT00054600","Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease",[39],[1270],[1254],{"nctId":1279,"briefTitle":1280,"status":55,"phases":1281,"primaryCompletion":1282,"completion":118,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1287},"NCT00221000","Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis",[39],"2006-10","2003-08",86,[1286],"Rheumatoid Arthritis",[1254],{"trials":1289,"activeCount":9},[],{"trials":1291,"activeCount":9},[],{"trials":1293,"activeCount":9},[],{"intervention":530,"totalTrials":32,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1297,"activeCount":9},[],{"trials":1299,"activeCount":9},[],{"trials":1301,"activeCount":9},[1302,1306],{"nctId":688,"briefTitle":689,"status":55,"phases":1303,"primaryCompletion":70,"completion":70,"start":691,"enrollment":692,"conditions":1304,"interventions":1305},[38,39],[694],[696,696,530],{"nctId":523,"briefTitle":524,"status":55,"phases":1307,"primaryCompletion":504,"completion":526,"start":476,"enrollment":477,"conditions":1308,"interventions":1309},[39],[528],[484,530],{"trials":1311,"activeCount":9},[],{"trials":1313,"activeCount":9},[],{"trials":1315,"activeCount":9},[],{"intervention":1317,"totalTrials":134,"cells":1318},"Inhaled carbon monoxide",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1320,"activeCount":9},[],{"trials":1322,"activeCount":9},[],{"trials":1324,"activeCount":9},[1325],{"nctId":1326,"briefTitle":1327,"status":595,"phases":1328,"primaryCompletion":329,"completion":329,"start":997,"enrollment":9,"conditions":1329,"interventions":1331},"NCT00531856","Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients",[39],[1330],"Kidney Transplantation",[1317,1317,1317,1332,1332],"Inhaled Carbon Monoxide",{"trials":1334,"activeCount":9},[],{"trials":1336,"activeCount":9},[],{"trials":1338,"activeCount":9},[],{"intervention":1340,"totalTrials":134,"cells":1341},"PENNSAID Gel",{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1343,"activeCount":9},[],{"trials":1345,"activeCount":9},[],{"trials":1347,"activeCount":9},[1348],{"nctId":1349,"briefTitle":1350,"status":55,"phases":1351,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1357},"NCT01119898","Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis",[39],"2011-02-16","2010-08-02",260,[1356],"Osteoarthritis of the Knee",[1340,1358],"Vehicle",{"trials":1360,"activeCount":9},[],{"trials":1362,"activeCount":9},[],{"trials":1364,"activeCount":9},[],{"intervention":1358,"totalTrials":134,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1368,"activeCount":9},[],{"trials":1370,"activeCount":9},[],{"trials":1372,"activeCount":9},[1373],{"nctId":1349,"briefTitle":1350,"status":55,"phases":1374,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1375,"interventions":1376},[39],[1356],[1340,1358],{"trials":1378,"activeCount":9},[],{"trials":1380,"activeCount":9},[],{"trials":1382,"activeCount":9},[],{"intervention":1384,"totalTrials":134,"cells":1385},"Sodium Sulfide (Na2S) for",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1387,"activeCount":9},[],{"trials":1389,"activeCount":9},[],{"trials":1391,"activeCount":9},[1392],{"nctId":1393,"briefTitle":1394,"status":595,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1396,"enrollment":9,"conditions":1397,"interventions":1399},"NCT01007461","IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction",[39],"2009-12",[1398],"ST-Segment Elevation Myocardial Infraction",[1384],{"trials":1401,"activeCount":9},[],{"trials":1403,"activeCount":9},[],{"trials":1405,"activeCount":9},[],{"intervention":1407,"totalTrials":134,"cells":1408},"H.P. Acthar® Gel",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1410,"activeCount":9},[],{"trials":1412,"activeCount":9},[],{"trials":1414,"activeCount":9},[1415],{"nctId":1416,"briefTitle":1417,"status":595,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":9,"conditions":1421,"interventions":1423},"NCT02113735","Safety and Efficacy Study of Acthar in Subjects With ARDS",[39],"2016-08","2014-08",[1422],"Acute Respiratory Distress Syndrome",[1407],{"trials":1425,"activeCount":9},[],{"trials":1427,"activeCount":9},[],{"trials":1429,"activeCount":9},[],{"intervention":1431,"totalTrials":134,"cells":1432},"Methoxsalen +ECP",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1434,"activeCount":9},[],{"trials":1436,"activeCount":9},[],{"trials":1438,"activeCount":9},[1439],{"nctId":1440,"briefTitle":1441,"status":55,"phases":1442,"primaryCompletion":505,"completion":505,"start":585,"enrollment":1443,"conditions":1444,"interventions":1446},"NCT00221026","Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease",[39],25,[1445],"Crohn's Disease",[1431],{"trials":1448,"activeCount":9},[],{"trials":1450,"activeCount":9},[],{"trials":1452,"activeCount":9},[],{"intervention":1454,"totalTrials":134,"cells":1455},"Raplixa",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1457,"activeCount":9},[],{"trials":1459,"activeCount":9},[],{"trials":1461,"activeCount":9},[1462],{"nctId":1463,"briefTitle":1464,"status":130,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":195,"conditions":1469,"interventions":1470},"NCT02117349","Topical Raplixa for Surgical Bleeding in Children",[39],"2017-11-17","2018-03-06","2014-12-04",[31],[1454,1471],"Rescue treatment",{"trials":1473,"activeCount":9},[],{"trials":1475,"activeCount":9},[],{"trials":1477,"activeCount":9},[],{"intervention":1471,"totalTrials":134,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":9},[],{"trials":1483,"activeCount":9},[],{"trials":1485,"activeCount":9},[1486],{"nctId":1463,"briefTitle":1464,"status":130,"phases":1487,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":195,"conditions":1488,"interventions":1489},[39],[31],[1454,1471],{"trials":1491,"activeCount":9},[],{"trials":1493,"activeCount":9},[],{"trials":1495,"activeCount":9},[],{"intervention":1497,"totalTrials":134,"cells":1498},"MNK-1411",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1500,"activeCount":9},[],{"trials":1502,"activeCount":9},[],{"trials":1504,"activeCount":9},[1505],{"nctId":1506,"briefTitle":1507,"status":130,"phases":1508,"primaryCompletion":1509,"completion":1509,"start":1510,"enrollment":1511,"conditions":1512,"interventions":1514},"NCT03400852","A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy",[39],"2020-02-25","2018-07-27",44,[1513],"Muscular Dystrophy, Duchenne",[1497],{"trials":1516,"activeCount":9},[],{"trials":1518,"activeCount":9},[],{"trials":1520,"activeCount":9},[],{"intervention":1522,"totalTrials":134,"cells":1523},"IK-1001",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1525,"activeCount":9},[],{"trials":1527,"activeCount":9},[],{"trials":1529,"activeCount":9},[1530],{"nctId":1531,"briefTitle":1532,"status":130,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":166,"conditions":1536,"interventions":1538},"NCT00858936","Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery",[39],"2010-04","2009-05",[1537],"Coronary Artery Bypass Surgery",[1522,1539],"Normal Saline",{"trials":1541,"activeCount":9},[],{"trials":1543,"activeCount":9},[],{"trials":1545,"activeCount":9},[],{"intervention":1539,"totalTrials":134,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1549,"activeCount":9},[],{"trials":1551,"activeCount":9},[],{"trials":1553,"activeCount":9},[1554],{"nctId":1531,"briefTitle":1532,"status":130,"phases":1555,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":166,"conditions":1556,"interventions":1557},[39],[1537],[1522,1539],{"trials":1559,"activeCount":9},[],{"trials":1561,"activeCount":9},[],{"trials":1563,"activeCount":9},[],{"intervention":1565,"totalTrials":134,"cells":1566},"MNK6106",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1568,"activeCount":9},[],{"trials":1570,"activeCount":9},[],{"trials":1572,"activeCount":9},[1573],{"nctId":1574,"briefTitle":1575,"status":55,"phases":1576,"primaryCompletion":224,"completion":224,"start":1577,"enrollment":147,"conditions":1578,"interventions":1581},"NCT03712280","MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)",[39],"2018-12-01",[1579,1580],"Hepatic Cirrhosis","Hepatic Encephalopathy (HE)",[1565,1582],"Rifaximin",{"trials":1584,"activeCount":9},[],{"trials":1586,"activeCount":9},[],{"trials":1588,"activeCount":9},[],{"intervention":1582,"totalTrials":134,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1592,"activeCount":9},[],{"trials":1594,"activeCount":9},[],{"trials":1596,"activeCount":9},[1597],{"nctId":1574,"briefTitle":1575,"status":55,"phases":1598,"primaryCompletion":224,"completion":224,"start":1577,"enrollment":147,"conditions":1599,"interventions":1600},[39],[1579,1580],[1565,1582],{"trials":1602,"activeCount":9},[],{"trials":1604,"activeCount":9},[],{"trials":1606,"activeCount":9},[],{"intervention":1608,"totalTrials":32,"cells":1609},"Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1611,"activeCount":9},[],{"trials":1613,"activeCount":9},[1614,1623],{"nctId":1615,"briefTitle":1616,"status":55,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1621},"NCT00853294","Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension",[38],"2003-09",42,[15],[1608,1622],"5 mL chlorpheniramine (8 mg\u002F5 mL)\u002Fhydrocodone (10 mg\u002F5 mL) extended release oral suspension",{"nctId":1624,"briefTitle":1625,"status":55,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1618,"enrollment":315,"conditions":1628,"interventions":1629},"NCT00853190","Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension",[38],"2003-10",[15],[1608,1622],{"trials":1631,"activeCount":9},[],{"trials":1633,"activeCount":9},[],{"trials":1635,"activeCount":9},[],{"trials":1637,"activeCount":9},[],{"intervention":1622,"totalTrials":32,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1652,"PHASE3":1654,"PHASE4":1656,"NA":1658},{"trials":1641,"activeCount":9},[],{"trials":1643,"activeCount":9},[1644,1648],{"nctId":1615,"briefTitle":1616,"status":55,"phases":1645,"primaryCompletion":1618,"completion":1618,"start":1618,"enrollment":1619,"conditions":1646,"interventions":1647},[38],[15],[1608,1622],{"nctId":1624,"briefTitle":1625,"status":55,"phases":1649,"primaryCompletion":1627,"completion":1627,"start":1618,"enrollment":315,"conditions":1650,"interventions":1651},[38],[15],[1608,1622],{"trials":1653,"activeCount":9},[],{"trials":1655,"activeCount":9},[],{"trials":1657,"activeCount":9},[],{"trials":1659,"activeCount":9},[],{"intervention":1661,"totalTrials":32,"cells":1662},"Controlled-Release Oxycodone Hydrochloride 40 mg",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1664,"activeCount":9},[],{"trials":1666,"activeCount":9},[1667,1674],{"nctId":1668,"briefTitle":1669,"status":55,"phases":1670,"primaryCompletion":516,"completion":516,"start":516,"enrollment":304,"conditions":1671,"interventions":1672},"NCT00853268","Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets",[38],[15],[1661,1673],"OxyContin® 40 mg",{"nctId":1675,"briefTitle":1676,"status":55,"phases":1677,"primaryCompletion":516,"completion":516,"start":516,"enrollment":304,"conditions":1678,"interventions":1679},"NCT00853892","Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets",[38],[15],[1661,1673],{"trials":1681,"activeCount":9},[],{"trials":1683,"activeCount":9},[],{"trials":1685,"activeCount":9},[],{"trials":1687,"activeCount":9},[],{"intervention":1673,"totalTrials":32,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1691,"activeCount":9},[],{"trials":1693,"activeCount":9},[1694,1698],{"nctId":1668,"briefTitle":1669,"status":55,"phases":1695,"primaryCompletion":516,"completion":516,"start":516,"enrollment":304,"conditions":1696,"interventions":1697},[38],[15],[1661,1673],{"nctId":1675,"briefTitle":1676,"status":55,"phases":1699,"primaryCompletion":516,"completion":516,"start":516,"enrollment":304,"conditions":1700,"interventions":1701},[38],[15],[1661,1673],{"trials":1703,"activeCount":9},[],{"trials":1705,"activeCount":9},[],{"trials":1707,"activeCount":9},[],{"trials":1709,"activeCount":9},[],{"intervention":1711,"totalTrials":32,"cells":1712},"Oxycodone hydrochloride tablet 30 mg",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1732,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1714,"activeCount":9},[],{"trials":1716,"activeCount":9},[1717,1726],{"nctId":1718,"briefTitle":1719,"status":55,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":282,"conditions":1723,"interventions":1724},"NCT00853216","Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets",[38],"2003-02","2003-01",[15],[1711,1725],"Roxicodone™ tablet 30 mg",{"nctId":1727,"briefTitle":1728,"status":55,"phases":1729,"primaryCompletion":1721,"completion":1721,"start":1721,"enrollment":381,"conditions":1730,"interventions":1731},"NCT00853736","Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets",[38],[15],[1725,1711],{"trials":1733,"activeCount":9},[],{"trials":1735,"activeCount":9},[],{"trials":1737,"activeCount":9},[],{"trials":1739,"activeCount":9},[],{"intervention":1725,"totalTrials":32,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1743,"activeCount":9},[],{"trials":1745,"activeCount":9},[1746,1750],{"nctId":1718,"briefTitle":1719,"status":55,"phases":1747,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":282,"conditions":1748,"interventions":1749},[38],[15],[1711,1725],{"nctId":1727,"briefTitle":1728,"status":55,"phases":1751,"primaryCompletion":1721,"completion":1721,"start":1721,"enrollment":381,"conditions":1752,"interventions":1753},[38],[15],[1725,1711],{"trials":1755,"activeCount":9},[],{"trials":1757,"activeCount":9},[],{"trials":1759,"activeCount":9},[],{"trials":1761,"activeCount":9},[],{"intervention":1763,"totalTrials":134,"cells":1764},"Hydromorphone Hydrochloride tablet 8 mg",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1778,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1766,"activeCount":9},[],{"trials":1768,"activeCount":9},[1769],{"nctId":1770,"briefTitle":1771,"status":55,"phases":1772,"primaryCompletion":1773,"completion":1773,"start":1773,"enrollment":1774,"conditions":1775,"interventions":1776},"NCT00853554","Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets",[38],"2002-12",24,[15],[1763,1777],"Dilaudid® tablet 8 mg",{"trials":1779,"activeCount":9},[],{"trials":1781,"activeCount":9},[],{"trials":1783,"activeCount":9},[],{"trials":1785,"activeCount":9},[],{"intervention":1777,"totalTrials":134,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1789,"activeCount":9},[],{"trials":1791,"activeCount":9},[1792],{"nctId":1770,"briefTitle":1771,"status":55,"phases":1793,"primaryCompletion":1773,"completion":1773,"start":1773,"enrollment":1774,"conditions":1794,"interventions":1795},[38],[15],[1763,1777],{"trials":1797,"activeCount":9},[],{"trials":1799,"activeCount":9},[],{"trials":1801,"activeCount":9},[],{"trials":1803,"activeCount":9},[],{"intervention":1805,"totalTrials":134,"cells":1806},"MNK-155",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1808,"activeCount":9},[],{"trials":1810,"activeCount":9},[1811],{"nctId":1812,"briefTitle":1813,"status":595,"phases":1814,"primaryCompletion":1815,"completion":1816,"start":302,"enrollment":9,"conditions":1817,"interventions":1818},"NCT02767349","Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain",[38],"2017-04","2017-06",[24],[1805],{"trials":1820,"activeCount":9},[],{"trials":1822,"activeCount":9},[],{"trials":1824,"activeCount":9},[],{"trials":1826,"activeCount":9},[],{"intervention":1828,"totalTrials":134,"cells":1829},"Oxycodone hydrochloride tablet 15 mg",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1841,"PHASE3":1843,"PHASE4":1845,"NA":1847},{"trials":1831,"activeCount":9},[],{"trials":1833,"activeCount":9},[1834],{"nctId":1835,"briefTitle":1836,"status":55,"phases":1837,"primaryCompletion":1721,"completion":1721,"start":1721,"enrollment":282,"conditions":1838,"interventions":1839},"NCT00853320","Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets",[38],[15],[1828,1840],"Roxicodone™ tablet 15 mg",{"trials":1842,"activeCount":9},[],{"trials":1844,"activeCount":9},[],{"trials":1846,"activeCount":9},[],{"trials":1848,"activeCount":9},[],{"intervention":1840,"totalTrials":134,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1852,"activeCount":9},[],{"trials":1854,"activeCount":9},[1855],{"nctId":1835,"briefTitle":1836,"status":55,"phases":1856,"primaryCompletion":1721,"completion":1721,"start":1721,"enrollment":282,"conditions":1857,"interventions":1858},[38],[15],[1828,1840],{"trials":1860,"activeCount":9},[],{"trials":1862,"activeCount":9},[],{"trials":1864,"activeCount":9},[],{"trials":1866,"activeCount":9},[],{"intervention":1868,"totalTrials":134,"cells":1869},"Sodium Sulfide",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1871,"activeCount":9},[],{"trials":1873,"activeCount":9},[1874],{"nctId":1875,"briefTitle":1876,"status":130,"phases":1877,"primaryCompletion":1878,"completion":1878,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1883},"NCT00879645","Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function",[38],"2010-03","2009-08",28,[1882],"Renal Impairment",[1868,1868,1868,1868],{"trials":1885,"activeCount":9},[],{"trials":1887,"activeCount":9},[],{"trials":1889,"activeCount":9},[],{"trials":1891,"activeCount":9},[],{"intervention":1893,"totalTrials":134,"cells":1894},"MNK-010",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1896,"activeCount":9},[],{"trials":1898,"activeCount":9},[1899],{"nctId":1900,"briefTitle":1901,"status":130,"phases":1902,"primaryCompletion":1903,"completion":1904,"start":314,"enrollment":1511,"conditions":1905,"interventions":1907},"NCT02040558","Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors",[38],"2016-05","2016-07",[1906],"Advanced Solid Tumors",[1893],{"trials":1909,"activeCount":9},[],{"trials":1911,"activeCount":9},[],{"trials":1913,"activeCount":9},[],{"trials":1915,"activeCount":9},[],{"intervention":1917,"totalTrials":134,"cells":1918},"2% w\u002Fw diclofenac sodium topical gel",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1920,"activeCount":9},[],{"trials":1922,"activeCount":9},[1923],{"nctId":1924,"briefTitle":1925,"status":55,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":10,"conditions":1929,"interventions":1930},"NCT01202799","Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel",[38],"2010-11","2010-09",[18],[1917,1931,1932],"1.5% w\u002Fw diclofenac sodium topical solution","75 mg diclofenac sodium delayed release",{"trials":1934,"activeCount":9},[],{"trials":1936,"activeCount":9},[],{"trials":1938,"activeCount":9},[],{"trials":1940,"activeCount":9},[],{"intervention":1931,"totalTrials":134,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":9},[],{"trials":1946,"activeCount":9},[1947],{"nctId":1924,"briefTitle":1925,"status":55,"phases":1948,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":10,"conditions":1949,"interventions":1950},[38],[18],[1917,1931,1932],{"trials":1952,"activeCount":9},[],{"trials":1954,"activeCount":9},[],{"trials":1956,"activeCount":9},[],{"trials":1958,"activeCount":9},[],{"intervention":1932,"totalTrials":134,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1969,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1962,"activeCount":9},[],{"trials":1964,"activeCount":9},[1965],{"nctId":1924,"briefTitle":1925,"status":55,"phases":1966,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":10,"conditions":1967,"interventions":1968},[38],[18],[1917,1931,1932],{"trials":1970,"activeCount":9},[],{"trials":1972,"activeCount":9},[],{"trials":1974,"activeCount":9},[],{"trials":1976,"activeCount":9},[],{"intervention":1978,"totalTrials":134,"cells":1979},"Test fentanyl citrate 400 mcg troche",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1981,"activeCount":9},[],{"trials":1983,"activeCount":9},[1984],{"nctId":1985,"briefTitle":1986,"status":55,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1988,"enrollment":147,"conditions":1989,"interventions":1990},"NCT01173627","Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.",[38],"2006-08",[18],[1978,1991],"Actiq 400 mcg",{"trials":1993,"activeCount":9},[],{"trials":1995,"activeCount":9},[],{"trials":1997,"activeCount":9},[],{"trials":1999,"activeCount":9},[],{"intervention":1991,"totalTrials":134,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2003,"activeCount":9},[],{"trials":2005,"activeCount":9},[2006],{"nctId":1985,"briefTitle":1986,"status":55,"phases":2007,"primaryCompletion":1988,"completion":1988,"start":1988,"enrollment":147,"conditions":2008,"interventions":2009},[38],[18],[1978,1991],{"trials":2011,"activeCount":9},[],{"trials":2013,"activeCount":9},[],{"trials":2015,"activeCount":9},[],{"trials":2017,"activeCount":9},[],{"intervention":2019,"totalTrials":134,"cells":2020},"Oral solution OC\u002FAPAP",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2034,"PHASE3":2036,"PHASE4":2038,"NA":2040},{"trials":2022,"activeCount":9},[],{"trials":2024,"activeCount":9},[2025],{"nctId":2026,"briefTitle":2027,"status":55,"phases":2028,"primaryCompletion":2029,"completion":2030,"start":1419,"enrollment":692,"conditions":2031,"interventions":2033},"NCT02966860","Single-Dose PK Study of an Oxycodone\u002FAcetaminophen Solution in Healthy Subjects",[38],"2016-09","2016-11",[2032],"Healthy Volunteers",[2019],{"trials":2035,"activeCount":9},[],{"trials":2037,"activeCount":9},[],{"trials":2039,"activeCount":9},[],{"trials":2041,"activeCount":9},[],{"intervention":905,"totalTrials":134,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2058},{"trials":2045,"activeCount":9},[2046],{"nctId":898,"briefTitle":899,"status":55,"phases":2047,"primaryCompletion":901,"completion":901,"start":840,"enrollment":109,"conditions":2048,"interventions":2049},[37],[903],[905,893],{"trials":2051,"activeCount":9},[],{"trials":2053,"activeCount":9},[],{"trials":2055,"activeCount":9},[],{"trials":2057,"activeCount":9},[],{"trials":2059,"activeCount":9},[],{"intervention":2061,"totalTrials":134,"cells":2062},"INOmax",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2064,"activeCount":9},[],{"trials":2066,"activeCount":9},[],{"trials":2068,"activeCount":9},[],{"trials":2070,"activeCount":9},[],{"trials":2072,"activeCount":9},[],{"trials":2074,"activeCount":9},[2075],{"nctId":2076,"briefTitle":2077,"status":130,"phases":2078,"primaryCompletion":2079,"completion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2084},"NCT03132428","Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension",[],"2020-02-11","2017-07-27",140,[2083],"Pulmonary Hypertension of Newborn",[2061],{"intervention":2086,"totalTrials":134,"cells":2087},"Diclofenac",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2089,"activeCount":9},[],{"trials":2091,"activeCount":9},[],{"trials":2093,"activeCount":9},[],{"trials":2095,"activeCount":9},[],{"trials":2097,"activeCount":9},[],{"trials":2099,"activeCount":9},[2100],{"nctId":2101,"briefTitle":2102,"status":2103,"phases":2104,"conditions":2105,"interventions":2107},"NCT01579890","Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis","APPROVED_FOR_MARKETING",[],[2106],"Osteoarthritis of the Hand",[2086]]